AU6325899A - New compounds, their preparation and use - Google Patents
New compounds, their preparation and useInfo
- Publication number
- AU6325899A AU6325899A AU63258/99A AU6325899A AU6325899A AU 6325899 A AU6325899 A AU 6325899A AU 63258/99 A AU63258/99 A AU 63258/99A AU 6325899 A AU6325899 A AU 6325899A AU 6325899 A AU6325899 A AU 6325899A
- Authority
- AU
- Australia
- Prior art keywords
- preparation
- new compounds
- compounds
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/12—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D337/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA | 1998-05-28 | ||
DKPA199801356 | 1998-10-21 | ||
PCT/DK1999/000574 WO2000023417A1 (en) | 1998-10-21 | 1999-10-19 | New compounds, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6325899A true AU6325899A (en) | 2000-05-08 |
Family
ID=8103962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU63258/99A Abandoned AU6325899A (en) | 1998-10-21 | 1999-10-19 | New compounds, their preparation and use |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1123269A1 (en) |
JP (1) | JP2002527503A (en) |
AU (1) | AU6325899A (en) |
WO (1) | WO2000023417A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035437A2 (en) * | 1998-12-17 | 2000-06-22 | Mindset Biopharmaceuticals (Usa), Inc. | Improving mental performance by increasing brain insulin sensitivity |
EP1634605A3 (en) | 2000-03-08 | 2006-10-11 | Novo Nordisk A/S | treatment of dyslipidemia in a patient having type 2 diabetes |
US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
EP2243776A1 (en) | 2001-10-12 | 2010-10-27 | High Point Pharmaceuticals, LLC | Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor |
CZ2004747A3 (en) | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Amide derivatives functioning as GK activators |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
JP4881559B2 (en) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | Arylcarbonyl derivatives as therapeutic agents |
DE602004022153D1 (en) | 2003-05-14 | 2009-09-03 | High Point Pharmaceuticals Llc | COMPOUNDS FOR THE TREATMENT OF OBESITAS |
CA2539596A1 (en) | 2003-09-30 | 2005-04-07 | Kilian Waldemar Conde-Frieboes | Melanocortin receptor agonists |
ATE498404T1 (en) | 2003-12-09 | 2011-03-15 | Novo Nordisk As | REGULATION OF FOOD PREFERENCE WITH GLP-1 AGONISTS |
DK1723128T3 (en) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarlurines and their use as glucokinase activators |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
EP1758856A2 (en) | 2004-05-04 | 2007-03-07 | Novo Nordisk A/S | Indole derivatives for the treatment of obesity |
US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
JP2008521864A (en) | 2004-12-03 | 2008-06-26 | トランステック・ファーマ、インコーポレイテッド | Heteroaromatic glucokinase activator |
CN103110635A (en) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | Histamine H3 receptor antagonist |
CA2615938C (en) | 2005-07-14 | 2014-04-29 | Novo-Nordisk A/S | Urea glucokinase activators |
WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
JP5198280B2 (en) | 2005-11-17 | 2013-05-15 | イーライ リリー アンド カンパニー | Glucagon receptor antagonists and their preparation and therapeutic use |
JP2009531376A (en) | 2006-03-28 | 2009-09-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | Benzothiazole having histamine H3 receptor activity |
NZ571972A (en) | 2006-05-29 | 2011-09-30 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
US7915299B2 (en) | 2006-11-15 | 2011-03-29 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
ES2377322T3 (en) | 2006-11-15 | 2012-03-26 | High Point Pharmaceuticals, Llc | New 2- (2-hydroxyphenyl) benzothiadiazines useful for the treatment of obesity and diabetes |
EP2099777B1 (en) | 2007-01-11 | 2015-08-12 | Novo Nordisk A/S | Urea glucokinase activators |
US20100274022A1 (en) * | 2007-04-26 | 2010-10-28 | Pharmafrontier Co., Ltd. | G protein-coupled receptor inhibitor and pharmaceutical product |
CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
ES2522968T3 (en) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
BR112012021231A2 (en) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product |
RU2559320C2 (en) | 2010-03-26 | 2015-08-10 | Ново Нордиск А/С | Novel glucagon analogues |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP3009136A1 (en) | 2011-01-31 | 2016-04-20 | Cadila Healthcare Limited | Treatment for lipodystrophy |
EP2670368A4 (en) | 2011-02-03 | 2015-04-15 | Pharmedica Ltd | New oral dissolving films for insulin administration, for treating diabetes |
EA025380B1 (en) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
CA2830974A1 (en) | 2011-03-28 | 2012-10-04 | Jesper F. Lau | Novel glucagon analogues |
KR20140070612A (en) | 2011-09-23 | 2014-06-10 | 노보 노르디스크 에이/에스 | Novel glucagon analogues |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
KR20150036245A (en) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | Antidiabetic tricyclic compounds |
RU2015140066A (en) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC BICYCLIC COMPOUNDS |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
UA114360C2 (en) | 2013-04-22 | 2017-05-25 | Каділа Хелткере Лімітед | A novel composition for nonalcoholic fatty liver disease (nafld) |
US20160107989A1 (en) | 2013-05-30 | 2016-04-21 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
TW201636015A (en) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | Synergistic compositions |
IN2013MU02470A (en) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US20180243263A1 (en) | 2016-12-09 | 2018-08-30 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
MA49883A (en) | 2017-03-15 | 2021-04-21 | Novo Nordisk As | BICYCLIC COMPOUNDS SUITABLE TO BIND TO MELANOCORTIN 4 RECEPTOR |
US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9508468A (en) * | 1994-07-29 | 1997-11-25 | Smithkline Beecham Plc | Compound process for the preparation of the same pharmaceutical composition processes for the treatment and / or prophylaxis of hyperglycemia in a human or non-human mammal and for the treatment of hyperlipidemia hypertension cardiovascular disease some eating disorders the treatment and / or prophylaxis of kidney disease prevention revers o stabilization or retardation of microalbuminuria progression in a human or non-human mammal use of the compound and intermediate compound |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
JPH10182550A (en) * | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | Hydroxybenzoic acid derivative and medicine containing the same as active ingredient |
WO1999019313A1 (en) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
-
1999
- 1999-10-19 EP EP99950504A patent/EP1123269A1/en not_active Withdrawn
- 1999-10-19 JP JP2000577145A patent/JP2002527503A/en active Pending
- 1999-10-19 WO PCT/DK1999/000574 patent/WO2000023417A1/en not_active Application Discontinuation
- 1999-10-19 AU AU63258/99A patent/AU6325899A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002527503A (en) | 2002-08-27 |
WO2000023417A1 (en) | 2000-04-27 |
EP1123269A1 (en) | 2001-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6325599A (en) | New compounds, their preparation and use | |
AU6325899A (en) | New compounds, their preparation and use | |
AU6190199A (en) | New compounds, their preparation and use | |
AU6325799A (en) | New compounds, their preparation and use | |
AU6190299A (en) | New compounds, their preparation and use | |
AU6325699A (en) | New compounds, their preparation and use | |
AU3958100A (en) | New compounds, their preparation and use | |
AU3958200A (en) | New compounds, their preparation and use | |
AU3957900A (en) | New compounds, their preparation and use | |
PL351312A1 (en) | New compounds, their preparation and use | |
HK1078561A1 (en) | Novel compounds, their use and preparation | |
AU2001248279A1 (en) | New compounds, their preparation and use | |
PL347371A1 (en) | Substituted phenyl derivatives, their preparation and use | |
PL351250A1 (en) | Antipicornaviral compounds, their preparation and use | |
EP1072266B8 (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
AU5638999A (en) | Dispersants, compositions and use | |
AU5970699A (en) | Use | |
AU3595099A (en) | New compounds, their preparation and use | |
AUPP584198A0 (en) | New use | |
AU5176299A (en) | Compound, composition and use | |
AU1046799A (en) | Compound, composition and use | |
AU6235799A (en) | New use | |
AU3700899A (en) | New compounds, their preparation and use | |
AU1046499A (en) | Compound, composition and use | |
AU1046399A (en) | Compound, composition and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |